Event Type
Disclosure
Mandatory
Variant
8-K
Unregistered Sales of Equity Securities. On February 20, 2026, Silo Pharma, Inc. (the “Company”) entered into an addendum to Service Agreement with its investor
Other Events. On February 23, 2026, the Company issued a press release announcing that the Company’s Board of Directors approved a stock repurchase program auth
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release of Silo Pharma, Inc. dated February 23, 2026 104 Cover Page Interact